Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax Aventis Pasteur MSD) in Ataxia-telangiectasia Patients.

Trial Profile

Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax Aventis Pasteur MSD) in Ataxia-telangiectasia Patients.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Mar 2010 Planned initiation date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 03 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top